Turning complex biomedical data into transformative insights
Products
We offer a range of rigorously developed products for precision medicine that empower your organization to generate valuable insights for drug development.
Pathology Foundation Models
Services
We offer custom services for complex image and data analysis from early drug discovery through regulated clinical applications.
Target & Biomarker Discovery
Translational Research
Enabling precision medicine for every patient
Our mission is to transform drug development and improve patient outcomes with AI that delivers novel insights for precision medicine.
Proprietary access to multimodal data
We have access to pathology samples and multimodal data from over 30M patients at leading university hospitals
and laboratories.
Deep biomedical expertise
Our team of data scientists, machine learning engineers, pathologists and biologists provide expert input and oversight into all of our products and services.
Advanced machine learning capabilities
Our machine learning approaches represent the frontier of AI - from industry-leading foundation models to advanced analytic techniques.
Cutting-edge collaborations with academic partners
We’ve established deep research collaborations with leading academic institutions in the EU and US.
Products and Services
We relentlessly innovate to ensure our products and services support the evolving needs of precision medicine research.
Interdisciplinary team with deep functional competency
Aignostics is a spin-off from Charité Berlin, one of Europe’s largest and most esteemed university hospitals. Today, our team has grown to include a diverse array of cross-functional experts working from our offices in Berlin and New York.
ISO 13485 and 27001 certified
GCP-ready clinical trial platform
Looking for an opportunity to work on something meaningful?
Join our diverse and fast-growing team to help revolutionize how cancer and other complex diseases are diagnosed and treated.
Case Studies
AI-Driven Target Discovery in LUSC: Validating a Multi-Omics Platform Through Rediscovery of Known and Novel Biology
The Aignostics-Bayer Target ID Platform integrates multi-omics data with explainable AI to identify complex biological patterns and reveal novel therapeutic hypotheses for cancers that lack effective treatments. Click below and fill out the form to see the full case study.
Enhanced Generalizability of Digital Pathology AI
This study discusses how our foundation model enhances the generalizability of a cell classification task. Click below and fill out the form to see the full case study.
Atlas H&E-TME: AI-Powered Tumor Microenvironment Analysis Product Overview
Atlas H&E-TME provides detailed insights about the tumor microenvironment in H&E-stained whole slide images. It is powered by Atlas 2, a leading foundation model codeveloped by Aignostics and Mayo Clinic.
